855477-01-9 Usage
General Description
3-Bromo-8-fluoroquinoline is a chemical compound with the molecular formula C10H6BrFN. It is a heterocyclic compound belonging to the quinoline family. This chemical is characterized by the presence of a bromine atom at the 3-position and a fluorine atom at the 8-position of the quinoline ring. It is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and materials. 3-Bromo-8-fluoroquinoline has applications in the development of new drugs and can be utilized in the pharmaceutical industry for the treatment of various diseases. Additionally, it may also find use in the synthesis of other functionalized quinolines for diverse chemical and biological studies.
Check Digit Verification of cas no
The CAS Registry Mumber 855477-01-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,5,4,7 and 7 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 855477-01:
(8*8)+(7*5)+(6*5)+(5*4)+(4*7)+(3*7)+(2*0)+(1*1)=199
199 % 10 = 9
So 855477-01-9 is a valid CAS Registry Number.
855477-01-9Relevant articles and documents
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 0845; 0846, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
